The transmission contains enzyme inhibitors associated with hydroxy thyroid inhibitors (Trk inhibitors). The pharmaceutical formulation includes 3 - (3-methoxy-4 - ((4-methoxy) oxygen) benzene) - 6 - (1-methyl-1h-pyrazol-4-il) - 3-pyridan [4,5-b] pyridine-2-amine. The properties of the microcrystalline suspension in the form of monohydrate are better than that in the form of dihydrate, and the formulation of long-term release. The long-term release drug formulation includes a micro SF filled with 3 - (3-methoxy-4 - ((4-methoxy) oxygen) benzene) - 6 - (1-methyl-1h-pyridine-4-il) - 3h-pyridine-2-amine.Se divulgan formulaciones farmacéuticas con un inhibidor de cinasa relacionada con tropomiosina (inhibidor de Trk). Las formulaciones farmacéuticas comprenden 3-(3-metoxi-4-((4-metoxibencil)oxi)bencil)-6-(1-metil-1H-pirazol-4-il)-3H-imidazo[4,5-b]piridin-2-amina en formulaciones de suspensión microcristalina en su forma de monohidrato, que muestra características mejoradas frente a la forma de anhidrato, y en formulaciones de liberación prolongada. Las formulaciones farmacéuticas de liberación prolongada comprenden microesferas cargadas con 3-(3-metoxi-4-((4-metoxibencil)oxi)bencil)-6-(1-metil-1H-pirazol-4-il)-3H-imidazo[4,5-b]piridin-2-amina.
